Physician profile
John T Siemon
NPI 1962819276
$6,564.23
in general payments reported to CMS, 2019-2025
31 companies · $1,612 in 2025
The $1,612 reported for 2025 was more than what 76% of Gynecologic Oncology providers received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $244 · 2021: $127 · 2022: $400 · 2023: $1,000 · 2024: $3,181 · 2025: $1,612.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,183 · Consulting Fee: $1,610.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,182.87 |
| Consulting Fee | $1,610.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Karyopharm Therapeutics INC. | $1,672.00 | 2024 | Xpovio |
| Myriad Genetic Laboratories, INC. | $797.25 | 2021-2025 | Myrisk, Precisetumor |
| Glaxosmithkline, LLC. | $527.24 | 2021-2025 | Jemperli, Zejula |
| Abbvie INC. | $474.34 | 2019-2025 | |
| Pfizer INC. | $451.51 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $444.85 | 2023-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Ethicon US, LLC | $399.48 | 2023-2025 | Monocryl, Stratafix, Vistaseal |
| Astrazeneca Pharmaceuticals Lp | $201.24 | 2024-2025 | Lynparza |
| Eisai INC. | $179.18 | 2023-2025 | |
| Sumitomo Pharma America, INC. | $161.09 | 2023-2025 | Myfembree |
| Medical Device Business Services, INC. | $139.99 | 2024 | Monocryl |
| Meditrina | $127.68 | 2024 | |
| Tesaro, INC. | $122.69 | 2019 | |
| Heron Therapeutics, INC. | $121.84 | 2025 | Aponvie, Zynrelef |
| Astellas Pharma US INC | $112.78 | 2024-2025 | Veozah |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Minerva Surgical, INC | $112.77 | 2023 | |
| Intuitive Surgical, INC. | $102.60 | 2022-2023 | Da Vinci Surgical System |
| Momentis Surgical INC. | $58.00 | 2022 | |
| Caris Mpi, INC. | $56.89 | 2025 | Mi Cancer Seek |
| Seagen INC. | $48.17 | 2023 | Tivdak |
| Tempus Ai, INC | $47.05 | 2024 | |
| Hologic Sales and Service, LLC | $32.61 | 2024 | Acessa Provu System |
| Verastem, INC. | $25.16 | 2025 | Avmapki Fakzynja Co-Pack |
| Olympus America INC. | $23.60 | 2023 | Olympus |
| Teleflex LLC | $22.58 | 2025 | Quikclot |
| Immunogen, INC. | $21.03 | 2023 | Elahere |
| Biotissue Holdings INC. | $17.61 | 2024 | |
| Fennec Pharmaceuticals, INC. | $17.57 | 2024 | Pedmark |
| Exeltis, USA INC. | $15.93 | 2025 | Slynd |
| Coopersurgical, INC. | $15.11 | 2025 | Ally II Ups |
| Axonics, INC. | $14.39 | 2023 | Axonics |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Siemon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.